Australia markets open in 7 hours 12 minutes

Johnson & Johnson (JNJ)

NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
152.19-1.21 (-0.79%)
As of 12:48PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close153.40
Open153.10
Bid152.15 x 800
Ask152.18 x 800
Day's range151.41 - 153.39
52-week range143.13 - 175.97
Volume2,551,036
Avg. volume7,422,514
Market cap366.273B
Beta (5Y monthly)0.55
PE ratio (TTM)22.61
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield4.96 (3.21%)
Ex-dividend date20 May 2024
1y target estN/A
  • GuruFocus.com

    Johnson & Johnson's Dividend Analysis

    Johnson & Johnson (NYSE:JNJ) recently announced a dividend of $1.24 per share, payable on 2024-06-04, with the ex-dividend date set for 2024-05-20. Using the data from GuruFocus, let's delve into Johnson & Johnson's dividend performance and assess its sustainability. What Does Johnson & Johnson Do?

  • Simply Wall St.

    Johnson & Johnson Insiders Sell US$6.8m Of Stock, Possibly Signalling Caution

    The fact that multiple Johnson & Johnson ( NYSE:JNJ ) insiders offloaded a considerable amount of shares over the past...

  • Reuters

    J&J-backed startup Rapport files for US IPO

    Rapport, which develops small molecule medicines for patients suffering from central nervous system disorders, is gearing up for a listing as the IPO market recovers from a slump amid increasing hopes of a soft landing for the economy. The company said it will be selling shares in the IPO, but did not disclose how many nor the price range. Rapport's net loss widened to $34.8 million in 2023 from $10.7 million a year earlier.